(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 455.28% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Humacyte's revenue in 2025 is $517,000.On average, 2 Wall Street analysts forecast HUMA's revenue for 2025 to be $1,359,616,422, with the lowest HUMA revenue forecast at $1,101,343,594, and the highest HUMA revenue forecast at $1,617,889,251. On average, 2 Wall Street analysts forecast HUMA's revenue for 2026 to be $6,015,507,684, with the lowest HUMA revenue forecast at $5,108,062,611, and the highest HUMA revenue forecast at $6,922,952,758.
In 2027, HUMA is forecast to generate $14,342,285,727 in revenue, with the lowest revenue forecast at $14,095,646,810 and the highest revenue forecast at $14,588,924,645.